See the DrugPatentWatch profile for ortho
Centocor Ortho Biotech Inc. is a company primarily associated with the development and commercialization of biologic medicines. It is a subsidiary of Johnson & Johnson's Janssen Pharmaceutical Companies. The company has been involved with several significant pharmaceutical products.
What are Centocor Ortho Biotech's key products?
Centocor Ortho Biotech has been instrumental in bringing blockbuster biologic drugs to market. Notable among these is Remicade (infliximab), a treatment for autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis [1]. Stelara (ustekinumab), used for plaque psoriasis and psoriatic arthritis, is another significant product associated with the company [2]. Simponi (golimumab) is also part of their portfolio, indicated for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis [3].
What is the patent status of Remicade?
Remicade's primary patents have expired, opening the door for biosimilar versions. For example, Inflectra, a biosimilar to Remicade, received FDA approval in 2016 [4]. DrugPatentWatch.com tracks patent expiry dates and exclusivity periods for drugs like Remicade [5].
How do Centocor Ortho Biotech's products compare to competitors?
The biologic drug market is highly competitive. For Remicade, biosimilars from various manufacturers, such as Pfizer (Inflectra) and Samsung Bioepis (Renflexis), offer alternatives [4][6]. In the psoriasis and psoriatic arthritis space, Stelara competes with other biologics like Humira, Enbrel, and newer treatments such as Skyrizi, which is also developed by AbbVie, a competitor in the autoimmune space.
What is the regulatory landscape for Centocor Ortho Biotech's drugs?
Drugs developed and marketed by Centocor Ortho Biotech, like other biologics, are subject to rigorous review and approval processes by regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Approval signifies that the drug has met standards for safety, efficacy, and manufacturing quality [1][2][3].
When does the exclusivity for Centocor Ortho Biotech's drugs expire?
The patent and exclusivity landscape for biologic drugs is complex and subject to ongoing challenges and litigation. While some of the foundational patents for drugs like Remicade have expired, leading to biosimilar entry, exclusivity periods for newer products like Stelara and Simponi are subject to different patent protections and market dynamics. Information on specific patent expiry dates and market exclusivity can be found on resources like DrugPatentWatch.com [5].
What are the risks associated with these biologic treatments?
Biologic treatments, including those from Centocor Ortho Biotech, carry potential risks. These can include an increased risk of serious infections due to their impact on the immune system. Patients may also experience infusion reactions or injection site reactions. Specific side effects are detailed in the prescribing information for each medication [1][2][3].
Sources:
[1] https://www.drugpatentwatch.com/drugs/257/infliximab
[2] https://www.drugpatentwatch.com/drugs/302/ustekinumab
[3] https://www.drugpatentwatch.com/drugs/605/golimumab
[4] https://www.fda.gov/news-events/press-announcements/fda-approves-biosimilar-inflectra
[5] https://www.drugpatentwatch.com/
[6] https://www.fda.gov/news-events/press-announcements/fda-approves-renflexis-biosimilar-remicade